Holen Sie sich die Stockscreener-App
118.81
1.09%
1.28
Handel nachbörslich:
118.80
-0.01
-0.01%
Schlusskurs vom Vortag:
$117.53
Offen:
$118.365
24-Stunden-Volumen:
3.17M
Relative Volume:
1.00
Marktkapitalisierung:
$22.97B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-32.46
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
-3.62%
1M Leistung:
+47.44%
6M Leistung:
+210.45%
1J Leistung:
+190.35%
1-Tages-Spanne:
$116.55
$120.53
1-Wochen-Bereich:
$113.96
$124.49
52-Wochen-Spanne:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
118.81 | 22.72B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Stifel Raises Price Target for RVMD to $170 with Buy Rating | RV - GuruFocus
Jim Cramer Highlights “Takeover Interest” in Revolution Medicines - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM) - The Globe and Mail
Merck Weighs Revolution Medicines Buyout And Expands AI Oncology Bet - simplywall.st
Guggenheim Raises Price Target for Revolution Medicines (RVMD) t - GuruFocus
Is Revolution Medicines Inc. Equity Warrant stock attractive for retirement portfolios2025 Year in Review & Daily Technical Stock Forecast Reports - bollywoodhelpline.com
Revolution Medicines gains breakthrough therapy status for zoldonrasib - MSN
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
Revolution Medicines shares climb after FDA grants Orphan Drug Designation for pancreatic cancer treatment - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Revolution Medicines stock hits all-time high at 121.62 USD By Investing.com - Investing.com Nigeria
Aug Wrap: Should I hold or sell INNEOVA Holdings Limited nowOptions Play & Verified Technical Trade Signals - baoquankhu1.vn
Revolution Medicines’ Stock Jumped On RAS Drug Hopes And Buyout Chatter - Finimize
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighStill a Buy? - MarketBeat
Revolution Medicines stock hits all-time high at 121.62 USD - Investing.com
Revolution Medicines (RVMD) Price Target Increased by 10.10% to 92.82 - Nasdaq
Merck reportedly in talks to buy Revolution in huge $28–32bn deal - BioXconomy
What sentiment indicators say about Revolution Medicines Inc. stockPortfolio Allocation Tips & We Spotted the Next Tesla – See Inside - bollywoodhelpline.com
Revolution Medicines (BIT:1RVMD) Price Target Increased by 13.08% to 76.84 - Nasdaq
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Looking At Revolution Medicines's Recent Unusual Options Activity - Benzinga
J.P. Morgan: Revolution Awaits Key Readout As Merck Takeover Rumors Swirl - Citeline News & Insights
Mizuho Raises Price Target for RVMD to $143, Maintains Outperfor - GuruFocus
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective - GuruFocus
Revolution Medicines declines to comment on M&A speculation at conference - MSN
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Ru - GuruFocus
Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating - TipRanks
Revolution Medicines CEO Addresses Investor Questions on Merck Acquisition at J.P. Morgan Healthcare Conference - geneonline.com
Revolution Medicines stock gains as Stifel highlights strong PDAC position By Investing.com - Investing.com India
Revolution Medicines stock gains as Stifel highlights strong PDAC position - Investing.com
$30B ‘might not be enough’ for Revolution Medicines, says Stifel - TipRanks
With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition - statnews.com
RVMD Projects Significant Growth with Solid Financial Position b - GuruFocus
Revolution Medicines (RVMD) CEO Cancels Conference Appearance - GuruFocus
RVMD: Late-stage RAS-targeted therapies advance, with new resistance-overcoming drugs entering trials in 2026 - TradingView — Track All Markets
Revolution Medicines CEO says not commenting on ‘rumors or speculation’ - TipRanks
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus - TechStock²
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - sharewise.com
Tema Etfs LLC Has $5.93 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Pharmaceutical Giants Eye Revolution Medicines with $23 Billion Market Cap Amid Oncology M&A Surge - geneonline.com
Revolution Medicines: Take The Win And Sell Following Large Move Sparked By Buyout Rumors - Seeking Alpha
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree - Pharmaceutical Technology
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Merck Could Strike 30 Billion Deal for Revolution Medicines - Oncodaily
Merck in Talks to Acquire Revolution Medicines for Approximately $30 Billion - Intellectia AI
RVMD stock hits a record high on rumored takeover interest - MSN
Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN
AbbVie in advanced talks to buy cancer drugmaker Revolution Medicines, shares jump nearly 30% - MSN
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines - GuruFocus
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):